PCA3 messenger RNA species in benign and malignant prostate...

Details PCA3 messenger RNA species in benign and malignant prostate... PCA3 messenger RNA species in benign and malignant prostate...

2008-05-06

2008-05-06

Yu, Misook (Department: 1642)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S024330

Reexamination Certificate

active

07368545

ABSTRACT:
This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostrate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.

REFERENCES:
patent: 6261562 (2001-07-01), Xu et al.
patent: 6262245 (2001-07-01), Xu et al.
patent: 6395278 (2002-05-01), Xu et al.
patent: 6465611 (2002-10-01), Xu et al.
patent: 6528260 (2003-03-01), Blumenfeld et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2002/0035244 (2002-03-01), Cohen et al.
patent: 0 160 228 (1985-11-01), None
patent: 0 520 794 (1992-12-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 95/28498 (1995-10-01), None
patent: WO 96/14875 (1996-05-01), None
patent: WO 98/45420 (1998-10-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 01/25272 (2001-04-01), None
patent: WO 01/25273 (2001-04-01), None
patent: WO 01/34802 (2001-05-01), None
patent: WO 01/51633 (2001-07-01), None
patent: WO 01/60860 (2001-08-01), None
patent: WO 01/73032 (2001-10-01), None
patent: WO 02/24718 (2002-03-01), None
patent: WO 02/30268 (2002-04-01), None
Burgess et al., J of Cell Bio. 111:2129-2138, 1990.
Lazar et al. Molecular and Cellular Biology 8:1247-1252, 1988.
Bowie et al. Science, 247:1306-1310, 1990.
Bussemakers, et al. 1999, Cancer Research, 59:5975-9.
Entry “kit” in Merriam-Webster Online Dictionary downloaded on Dec. 27, 2005.
Matteucci, M.D. and M.H. Caruthers, “Synthesis of Deoxyoligonucleotides on a Polymer Support,”J. Am. Chem. Soc. 103:3185-3191, American Chemical Society (1981).
Miller, P.S. and P.O.P. Ts'o, “Chapter 30. Oligonucleotide Inhibitors of Gene Expression in Living Cells: New Opportunities in Drug Design,”Annu. Reports Medicinal Chem. 23:295-304, Academic Press, Inc. (1988).
Morvan, F. et al., “α-DNA I. Synthesis, characterization by high field1H-NMR, and base-pairing properties of the unnatural hexadeoxyribonucleotide α-[d(CpCpTpTpCpC)] with its complement β-[d(GpGpApApGpG)],”Nucl. Acids Res. 14:5019-5035, IRL Press Limited (1986).
Nielsen, P.E., “Applications of peptide nucleic acids,”Curr. Opin. Biotechnol. 10:71-75, Elsevier Science Ltd. (Feb. 1999).
Sutcliffe, J.G. et al., “Antibodies That React with Predetermined Sites on Proteins,”Science 219:660-666, Association for the Advancement of Science (1983).
Verkaik, N.S. et al., “Clinical usefulness of RT-PCR detection of hematogenous prostate cancer spread,”Urol. Res. 25:373-384, Springer-Verlag (1997).
Walker, G.T. et al., “Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system,”Proc. Natl. Acad. Sci. USA 89:392-396, National Academy of Sciences of the USA (1992).
Walker, G.T. et al., “Strand displacement amplification—an isothermal, in vitro DNA amplification technique,”Nucl. Acids Res. 20:1691-1696, Oxford University Press (1992).
Weiss, R., “Hot Prospect for New Gene Amplifier,”Science 254:1292-1293, Association for the Advancement of Science (1991).
Syfpeithi at http://134.2.96.221/scripts/MHCServer,dll/home.htm (Mar. 13, 2001).
Israeli, R.S. et al., “Sensitive Nested Reverse Transcription Polymerase Chain Reaction Detection of Circulating Prostatic Tumor Cells: Comparison of Prostate-specific Membrane Antigen and Prostate-specific Antigen-based Assays,”Cancer Res. 54:6306-6310, American Association for Cancer Research (1994).
Kirby, R.S., “Pre-treatment staging of prostate cancer: recent advances and future prospects,”Prostate Cancer and Prostatic Dis. 1:2-10, Stockton Press (1997).
Kwoh, D.Y. et al., “Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format,”Proc. Natl. Acad. Sci. USA 86:1173-1177, National Academy of Sciences of the USA (1989).
Brawer, M.K. et al., “Screening for Prostatic Carcinoma with Prostate Specific Antigen,”J. Urology 147:147-841-845, American Urological Association, Inc. (1992).
El-Shirbiny, A.M., “Prostatic Specific Antigen,”Adv. Clinical Chem. 31:99-133, Academic Press, Inc. (1994).
Gomella, L.G. et al., “Reverse Transcriptase Polymerase Chain Reaction for Prostate Specific Antigen in the Management of Prostate Cancer,”J. Urology 158:326-337, American Urological Association, Inc. (1997).
Lange, P.H., “Chapter 41. Tumor Markers in Prostate Cancer,” in:Principles and Practice of Genitourinary Oncology, Raghaven, D. et al., eds., Lippincott-Raven Publishers, Philadelphia, PA, pp. 417-425 (1997).
Letran, J.L. et al., “Repeat Ultrasound Guided Prostate Needle Biopsy: Use of Free-To-Total Prostate Specific Antigen Ratio in Predicting Prostatic Carcinoma,”J. Urology 160:426-429, American Urological Association, Inc. (Aug. 1998).
Lizardi, P.M. et al., “Exponential Amplification of Recombinant-RNA Hybridization Probes,”Biotechnology 6:1197-1102, Nature Publishing Co. (1988).
Tamimi, Y., et al., DiagnoGene PCA3 reliable NASBA based reagents for detecting PCA3 mRNA, a recently described prostate marker,Proc. Am. Assoc. Cancer Res. 39:234 Poster Abstract (1998).
Bussemakers, M.J. and Isaacs, W.B., “Identification of Genes Associated with Prostate Cancer Development,”Urol. Res. 21:452, Abstract No. P42, Springer International (1993).
Bussemakers, M.J.G. and Isaacs, W.B., “Identification of Genes Associated with Prostate Cancer Development,”8th Annual Spring Meeting, Society for Basic Urologic Research, one page, Society for Basic Urologic Research (May 1994).
Bussemakers, M.J.G., et al., “Identification of DD3: A New Gene Overexpressed in Prostatic Tumors,”Urol. Res. 23:253, Abstract No. 0 36, Springer International (Aug. 1995).
Bussemakers, M.J.G., et al., “DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors,”Fall Symposium, Society for Basic Urologic Research, one page, Society for Basic Urologic Research (Dec. 1995).
Bussemakers, M.J.G., et al., “DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors,”Breast and Prostate Cancer: Basic Mechanisms, Abstract No. 102, pp. 17 (Jan.-Feb. 1996).
Bussemakers, M.J.G., et al., “DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors,”Meeting for the Dutch Association for Tumor Cell Biology(May 1996).
Gandini, O., “Is DD3 a New Prostate-specific Gene?,”Anticancer Res. 23:305-308, J.G. Delinassios (Jan.-Feb. 2003).
Co-Pending U.S. Appl. No. 09/996,953, Bussemakers, et al., filed Nov. 30, 2001 (Not Published).
Co-Pending U.S. Appl. No. 60/445,436, filed Feb. 7, 2003 (Not Published).
Co-Pending U.S. Appl. No. 09/402,713, Bussemakers, M.J., filed Oct. 8, 1999 (Published).
Bussemakers, M.J.G., “Changes in Gene Expression and Targets for Therapy,”Eur. Urol. 35:408-412, S. Karger AG (May 1999).
Bussemakers, M.J.G., et al., “DD3: A New Prostate-specific Gene, Highly Overexpressed in Prostate Cancer,”Canc. Res. 59:5975-5979, American Association for Cancer Research (Dec. 1999).
Bussemakers, M.J.G., et al., “DD3: a new prostate specific marker, overexpressed in prostatic tumors,”Proc. Annu. Meet. Amer. Assoc. Cancer Res. 87:515, Abstract No. 3522, American Association for Cancer Research (1996).
Bussemakers, M.J.G., et al., “DD3: A New Prostate-Specific Marker Strongly Overexpressed in Prostatic Tumors,”Urol. Res. 25:76, Abstract No. 02.2, Springer-Verlag (1997).
Bussemakers, M.J.G., et al., “Assessment of

Affiliated with

Also associated with

Rating

PCA3 messenger RNA species in benign and malignant prostate... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PCA3 messenger RNA species in benign and malignant prostate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PCA3 messenger RNA species in benign and malignant prostate... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2811241